Certara Leaders Discuss Leveraging RWD to Advance R&D and Meet Global Payers’ Needs
Certara’s Lee Stern and Shawn Bates shared their thoughts on how real world data (RWD) can be leveraged to meet [...]
CEVR Director Publishes Article on Improving Data Dashboards for Drug Value Assessments
Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center Peter Neumann [...]
Takeda Partners With Point32Health to Offer Value-Based Oncology Program in US
Takeda has partnered with Point32Health in a new value-based oncology program. Alunbrig, used in non-small cell lung cancer, is the [...]
Cost-Effectiveness Analyses Fail to Consider Health Equity
Although an important tool in assessing a drug’s value, cost-effectiveness analyses (CEAs) fail to account for health equity. Important information [...]
ISPOR Director Discusses Global Commitment to Improving HEOR
Director of Global Networks at the International Society for Pharmacoeconomics and Outcomes (ISPOR) Robert Selby discussed ISPOR’s worldwide initiative intended to [...]
PRMA Consulting Leader Discusses the Rapidly Increasing Influence of ICER’s Value Access Frameworks
Senior Principal at PRMA Consulting Emily Coriale discusses how value assessments put forth by the Institute for Clinical and Economic [...]
PRMA Consulting Senior Advisor Discusses the Four Pillars of Market Access and New Pharma Trends
Senior Advisor, Asia-Pacific at PRMA Consulting Jeff Weisel shared an update to his previous article detailing the four strategic pillars [...]
ICER Meets With FDA, EMA, and FDA to Discuss RWE Procedures
In a recent meeting, members of the Institute for Clinical and Economic Review (ICER), the Food and Drug Administration (FDA), [...]
MedPAC Talks Value-Based Healthcare and International Reference Pricing As Aduhelm Cost Sounds Alarms
The Medicare Payment Advisory Commission (MedPAC) is considering a series of measures that would reduce healthcare costs, including international reference pricing [...]
CMMI Director Discusses Value-Based Care and Improving Health Equity
Center for Medicare and Medicaid Innovation (CMMI) Director Liz Fowler discussed value-based payment models and improving existing healthcare models in [...]
Syneos Health Executive VP and Data Expert Discusses RWE and Aetion Collaboration
Executive Vice President of Real World Evidence (RWE) and Late Phase at Syneos Health Javier Jimenez discusses major industry trends [...]
New EMWA Article Explores Health Economic Evaluations and CHEERS Guidelines
An article published in the European Medical Writers Association’s Medical Writing journal explores the role of health economic evaluations in [...]
Upcoming ISPOR Webinar on Value in Healthcare Decision-Making
The International Society for Pharmacoeconomics and Outcomes (ISPOR) will hold a webinar on decision-making in healthcare on October 26th at 11:00 [...]
How Can NMAs and ITCs Add Value to HTAs?
The Evidence Base recently interviewed Dutch researcher Daan Reid. He shared his thoughts on health technology assessments (HTAs) and improving [...]
ICER VP Discusses Adding the Patient Voice to Value Assessments
Vice President of Patient Engagement at the Institute for Clinical and Economic Review (ICER) Yvette Venable highlights the importance of [...]
IQVIA Whitepaper on the Natural History of Disease Features Discussions on RWE, Big Data, and COVID-19
A recent IQVIA whitepaper brought together multidisciplinary experts to discuss the natural history of disease. The discussion focused on the [...]
HTAs Fail to Address Healthcare Disparities in Value Assessments
Health and healthcare disparities continue to impact care and outcomes in diverse patient populations. Health technology assessments (HTAs) fail to [...]
New GRACE Cost-Effectiveness Tool Considers Patients’ Wishes and Improves Healthcare Decision-Making
The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) tool addresses some of the challenges associated with previous health economics and outcomes research (HEOR) [...]
Biden’s Prescription Drug Price Plan Addresses Innovation and Omits Key Topics
President Biden’s drug pricing plan was published on September 9th. It includes key policy reforms such as allowing Medicare to [...]
ICER Whitepaper Proposes Improvements to the FDA’s Accelerated Approval Pathway
The Institute for Clinical and Economic Review (ICER) has released a whitepaper proposing policy reforms that would improve the Food and Drug [...]
BMJ Article Questions the Use of Surrogate Endpoints in Drug Assessments
An article published in the British Medical Journal (BMJ) details the controversial use of surrogate endpoints in assessing a drug’s [...]
Intermountain Healthcare and SCL Health Announce Merger; Resulting $11 Billion Health System to Span Six States
Intermountain Healthcare and SCL Health plan to merge, leading to a health system spanning six states. The $11 billion system [...]
Register Today for Upcoming World Congress Webinar Highlighting Four Common Value and Evidence Misconceptions
World Congress will host a webinar at 1:00 PM ET on September 21st, 2021. Consultant Pamela Divack will discuss common [...]
ISPOR Seeks Survey Respondents to Identify Key HEOR Trends
The Professional Society for Health Economics and Outcomes Research (ISPOR) has issued a survey to understand key trends in health [...]
HealthEconomics.Com Announces Results of 2021 Insight Survey on Value Communication
HealthEconomics.Com, a Scientist.com company, reported the findings of its 2021 Insight Survey on Value Communication in Pharma HEOR, RWE & [...]